On August 20, 2024, the Federal Trade Commission (FTC) submitted a comment supporting the FDA’s June 2024 draft guidance “Considerations for Demonstrating Interchangeability with a Reference ...
The Biosimilars Council recently commented on the FDA’s June 2024 Draft Guidance Docket No. FDA–2017-D-0154, which is focused on considerations regarding a switching study or studies intended ...